

#18

In re Letters Patent of: Ruben et al.	Docket No.: PZ006P1C1		
Patent No. 6,531,447	品		71
Issued: March 11, 2003		APR	ñ
For: Secreted Protein HEMCM42	CENTER 1600/2	0 <b>9</b> 2003	
	)0/2	<u>ယ</u> ;	

# APPLICATION FOR PATENT TERM ADJUSTMENT UNDER 37 C.F.R. § 1.705(d)

Commissioner for Patents Washington, D.C. 20231

Sir:

Applicants hereby request reconsideration of the patent term adjustment indicated on the face of U.S. Patent 6,531,447, which issued from Application No. 09/690,454 on March 11, 2003. This application includes the following attachments: (1) a Fee Transmittal Sheet with payment of the fee set forth in 37 C.F.R. § 1.18(e); (2) (Exhibit A) a copy of the title page of the issued patent; (3) (Exhibit B) a printout of the Patent Term Adjustment History obtained from PAIR; (4) (Exhibit C) a copy of the Letter Making Patent Office Error of Record, together with a copy of the corresponding PTO date-stamped Return Receipt Postcard; (5) (Exhibit D) a copy of the Official Gazette June 26, 2001 "Clarification of 37 C.F.R. § 1.704(c)(10)."

This request is being filed within 30 days of the date of issue and therefore is timely made. The fee required by 37 C.F.R. §§ 1.705(b)(1) has been paid, and the requirements of 37 C.F.R. §§ 1.705(b)(2) are satisfied by the following Statement of Facts.

Further, this request is made pursuant to 37 C.F.R. § 1.705(d) because Applicants filed a "Letter to Make PTO Error of Record" at the time of payment of the issue fee; this letter was not an amendment under 37 C.F.R. § 1.312, or other paper that caused substantial interference and delay in the patent issue process.

### STATEMENT OF FACTS

- (1) Issued U.S. Patent 6,531,447 indicates a patent term adjustment of 0 days. See Exhibit A. However, the correct patent term adjustment is 30 days. The grounds for patent term adjustment is provided by 37 C.F.R. § 1.702(a)(1), which specifies that the USPTO must "mail at least one of a notification under 35 U.S.C. § 132 or a notice of allowance under 35 U.S.C. § 151 no later than fourteen months after the date on which the application was filed under 35 U.S.C. § 111(a) or fulfilled the requirements of 35 U.S.C. § 371 in an international."
- (2) The period of adjustment due to examination delay is provided by 37 C.F.R. § 1.703(a)(1), which defines the period as "[t]he number of days, if any, in the period beginning on the day after the date that is fourteen months after the date on which the application was under 35 U.S.C. § 111(a) or fulfilled the requirements of 35 U.S.C. § 371 and ending on the date of mailing of either an action under 35 U.S.C. § 132, or a notice of allowance under 35 U.S.C. § 151, whichever occurs first." The application was filed on October 18, 2000 (see, Exhibit A). The adjustment period begins on December 19, 2001, which begins the fourteen-month period after filing the application. The adjustment period ends on January 17, 2002, which is the date the Restriction Requirement was mailed. Paper No. 7. Thus, the adjustment period is 30 days. See, Exhibit B.
- (4) Furthermore, the 30-day adjustment period was further reduced by 56 days (see, Exhibit B) attributed to Applicants' alleged delay because of filing a "Letter Making Patent Office Error of Record" with the payment of the issue fee on January 15, 2003. See, Exhibit C. This letter was sent to make of record an inconsequential error introduced by the PTO in the filing receipt. Such a minor error did not justify the issuance of a Certificate of Correction but Applicants felt that the error should appear in the prosecution history. This paper was erroneously entered in PAIR as a "312 Amendment." See, Exhibit B. With this letter, Applicants were not requesting an amendment under 37 C.F.R. § 1.312, which constitutes grounds for reducing the period of adjustment of patent term (see, 37 C.F.R. § 1.704(c)(10)). However, "only certain papers (not all papers), filed after a 'Notice of Allowance' is mailed, cause substantial interference and delay in the patent issue process" (emphasis added). See, 1274 OG 111, of June 26, 2001, submitted

as Exhibit D. Applicants assert that the "Letter Making Patent Office Error of Record" should

not be "considered a 'failure to engage in reasonable efforts' to conclude processing or

examination of an application," since such a paper did not require any further action or

consideration by the Patent Office.

(5) Given the above facts, Applicants should not be penalized any patent term during

prosecution, therefore, the correct patent term adjustment for U.S. Patent 6,531,447 should be 30

days.

(6) U.S. Patent 6,531,447 is not subject to any terminal disclaimer.

**CONCLUSION** 

Applicants respectfully request that the patent term adjustment for U.S. Patent 6,531,447

be reconsidered based on the facts described above and that Applicants' representatives be

notified of the result. Applicants believe that all of the requirements for such reconsideration

under 37 C.F.R. § 1.705(d), including payment of the appropriate fee, have been satisfied.

However, if clarification or further information is required, please call the undersigned at the

number listed below. If the fee included is incorrect or if there are any additional fees due in

connection with the filing of this paper, please charge the appropriate fees, or credit any

overpayment, to Deposit Account No. 08-3425. In the event of a favorable decision based on

this request, Applicants further request reimbursement of the fee which has been paid pursuant

to § 1.18(e), since payment of such fee was necessitated by a mistake of the Patent and

Trademark Office.

Dated: April 4, 2003

Respectfully submitted,

Janet M. Martineau

Registration No.: 46,903)

Attorney for Applicants

HUMAN GENOME SCIENCES, INC.

9410 Key West Avenue

Rockville, MD 20850

(301) 315-2723



# (12) United States Patent

Ruben et al.

(10) Patent No.:

US 6,531,447 B1

(45) Date of Patent:

Mar. 11, 2003

### (54) SECRETED PROTEIN HEMCM42

(75) Inventors: Steven M. Ruben, Olney, MD (US);
Craig A. Rosen, Laytonsville, MD
(US); Kenneth C. Carter, North
Potomac, MD (US); Patrick J. Dillon,
Carlsbad, CA (US); Gregory A.
Endress, Potomac, MD (US);
Guo-Liang Yu, Berkeley, CA (US);
Jian Ni, Rockville, MD (US); Ping

Feng, Gaithersburg, MD (US)

Assignee: Human Genome Sciences, Inc.,

Rockville, MD (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35

U.S.C. 154(b) by 0 days.

(21) Appl. No.: 09/690,454

(22) Filed: Oct. 18, 2000

### Related U.S. Application Data

- (63) Continuation of application No. 09/189,144, filed on Nov. 10, 1998, now abandoned, which is a continuation-in-part of application No. PCT/US98/10868, filed on May 28, 1998.
- (60) Provisional application No. 60/044,039, filed on May 30, 1997, provisional application No. 60/048,093, filed on May 30, 1997, provisional application No. 60/048,190, filed on May 30, 1997, provisional application No. 60/050,935, filed on May 30, 1997, provisional application No. 60/048,101, filed on May 30, 1997, provisional application No. 60/048, 356, filed on May 30, 1997, provisional application No. 60/056,250, filed on Aug. 29, 1997, provisional application No. 60/056,296, filed on Aug. 29, 1997, and provisional application No. 60/056,293, filed on Aug. 29, 1997.

(51)	Int. Cl.'	C07K 14/00
(52)	U.S. Cl	514/2; 530/300; 530/350
(58)	Field of Search	530/300 350

514/12

### (56) References Cited

### U.S. PATENT DOCUMENTS

6,207,642 B1 3/2001 Wiley

### FOREIGN PATENT DOCUMENTS

wo	PCT/US98/10868	10/1998		
wo	WO 98/54206	12/1998		
wo	WO 98/55508	12/1998		
wo	WO 99/61471	12/1999		
wo	WO 01/45730	6/2001		
wo	WO 01/45730	* 12/2001	A61K/3	8/17

### OTHER PUBLICATIONS

Genbank Accession No. AI768116 (Dec. 20, 1999). Hillier et al., Genbank Accession No. AA149044 (May 19, 1997).

Genbank Accession No. AW204761 (Dec. 2, 1999). Genbank Accession No. AI768403 (Dec. 20, 1999). Chen et al., Genbank Accession No. AA631934 (Oct. 20, 1997).

Genbank Accession No. AI221536 (Nov. 29, 1998).

Genbank Accession No. AW172990 (Nov. 16, 1999). Genbank Accession No. AW051452 (Sep. 20, 1999). Genbank Accession No. AW262030 (Dec. 28, 1999). Genbank Accession No. AI219327 (Nov. 29, 1998). Genbank Accession No. BF114971 (Oct. 24, 2000). Genbank Accession No. AI800959 (Dec. 19, 1999). Genbank Accession No. AI004154 (Aug. 27, 1998). Hillier et al., Genbank Accession No. AA149043 (May 19, 1997).

Genbank Accession No. AW338518 (Jan. 31, 2000). Genbank Accession No. AI568941 (May 14, 1999). Hillier et al., Genbank Accession No. N41733 (Jan. 24, 1996).

Genbank Accession No. AI827127 (Mar. 7, 2000). Lanfranchi et at., Genbank Accession No. F25336 (May 13, 1999).

Genbank Accession No. Al313436 (Feb. 3, 1999). Genbank Accession No. AA994944 (Aug. 27, 1998). Dias et al., Genbank Accession No. AW938942 (May 30, 2000).

Genbank Accession No. AI761510 (Dec 21, 2000). Genbank Accession No. BF063028 (Oct. 16, 2000). Genbank Accession No. AW628237 (Mar. 31, 2000). Hillier et al., Genbank Accession No. T56712 (Feb. 7, 1995). Hillier et al., Genbank Accession No. AI718198 (Jun. 10, 1999).

Hillier et al., Genbank Accession No. R48167 (May 18, 1995).

Genbank Accession No. BF108787 (Oct. 20, 2000). Genbank Accession No. BF197631 (Oct. 3, 2000). Genbank Accession No. AI767239 (Dec. 21, 1999). Genbank Accessio No. AW001699 (Mar. 8, 2000). Genbank Accession No. AI796303 (Dec. 20, 1999). Genbank Accession No. AI358289 (Feb. 15, 1999). Genbank Accession No. AW149867 (Nov. 3, 1999). Genbank Accession No. AA576558 (Sep. 9, 1997). Genbank Accession No. AI911799 (Dec. 17, 1999). Genbank Accession No. AA610401 (Dec. 9, 1997). Liew, Genbank Accession No. N83862 (Apr. 1, 1996). Genbank Accession No. AI470703 (Apr. 13, 1999). Genbank Accession No. BG236779 (Feb. 12, 2001). Genbank Accession No. AI470484 (Apr. 13, 1999). Genbank Accession No. AI492143 (Mar. 30, 1999). Hillier et al., Genbank Accession No. T74424 (Mar. 2,

### (List continued on next page.)

Primary Examiner—Karen Cochrane Carlson (74) Attorney, Agent, or Firm—Human Genome Sciences, Inc.

### (57) ABSTRACT

1995).

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

### 52 Claims, No Drawings

# Home

# UNITED STATES PATENT AND TRADEMARK OFFICE

Contact Us News & Notices eBusiness Center System Alerts Search Index

PATENT APPLICATION INFORMATION RETRIEVAL



PAIR

FAQ

Holp

Feedback

Other Links

1	Days	):30	):- 	:59	۱: 0	S
Patent Term Adjustment (PTA) for application number: 09/690,454		USPTO Delay (PTO):ქმ	Three Years:-	Applicant Delay (APPL):59	Total PTA:	Explanation of Calculations
t (PTA) for a		10-18-2000	03-11-2003	+0	+0	0+
Patent Term Adjustmen		Filing or 371(c) Date: 10-18-2000	Issue Date of Patent: 03-11-2003	Pre-Issue Petitions (days): +0	Post-Issue Petitions (days): +0	USPTO Adjustment (days): +0

File Contents History

Continuity Data

Full-text and images

View Maint. Statement

Class/Bubdlass GAU Information Employee Locator E-Business Center Patents

Information

Retrieve Maint. Fees to Pay

Maintenance Fees Available: Mon-Fri 5:30 AM to Midnight, Sat-Sun-Hol. 7:30 AM to 8:00 PM E.T. View Maint. Payment Windows Payment Window: 4

		Patent Term Adjustment History		
Number	Date	Contents Description	PTO (days)	APPL (days)
43	03-11-2003	Patent Issue Date Used in PTA Calculation	(adya)	(eda)
42	02-05-2003	2003 Receipt into Pubs		
41	01-30-2003	2003 Application Is Considered Ready for Issue		
40	01-15-2003	2003 Mailroom Date of Issue Fee Payment		
39	01-15-2003	Miscellaneous Incoming Letter		99
38	01-15-2003	2003 Workflow - 312 Amendment - Finish		
37	01-15-2003	01-15-2003 Workflow - 312 Amendment - Begin		_
36	01-15-2003	01-15-2003 Issue Fee Payment Recorded		
35	12-16-2002	Receipt into Pubs		
34	12-13-2002	12-13-2002 Sequence Forwarded to Pubs on Tape		
33	10-25-2002	10-25-2002 Workflow - File Sent to Contractor		
32	10-25-2002	2002 Receint into Puhs		

**PAIR Page** 

; ;	10 16 2002	40 45 0000 Mail Nation of Allemana	1
5	10-10-2002	Infall Notice of Allowalice	1
30	10-16-2002	Notice of Allowance Data Verification Completed	*
29	10-16-2002	Notice of Allowability	
28	10-08-2002	Date Forwarded to Examiner	
27	10-07-2002	Amendment after Final Rejection	
26	09-27-2002	Mail Final Rejection (PTOL - 326)	
25	09-27-2002	Final Rejection	
24	07-31-2002	Date Forwarded to Examiner	
23	07-29-2002	Response after Non-Final Action	3
22	07-31-2002	Mail Examiner Interview Summary (PTOL - 413)	Q.
21	07-03-2002	Examiner Interview Summary Record (PTOL - 413)	
19	04-26-2002	Mail Examiner Interview Summary (PTOL - 413)	U
18	04-26-2002	Mail Non-Final Rejection	
17	04-26-2002	Non-Final Rejection	
16	04-23-2002	Examiner Interview Summary Record (PTOL - 413)	
15	03-06-2002	Case Docketed to Examiner in GAU	
14	02-28-2002	X-Pre-Legal Complete Amended Case	
13	02-28-2002	Date Forwarded to Examiner	
12	02-19-2002	Response to Election / Restriction Filed	
11	02-19-2002	Information Disclosure Statement (IDS) Filed	
10	01-17-2002	Mail Restriction Requirement 30	
9	01-16-2002	Requirement for Restriction / Election	
8	10-19-2000	Preliminary Amendment	
7	01-07-2002	CRF is Good Technically / Entered into Database	
9	01-31-2001	Case Docketed to Examiner in GAU	
5	01-13-2001	Application Dispatched from OIPE	
4	01-13-2001	Application Is Now Complete	
3	01-07-2001	Correspondence Address Change	
2	11-03-2000	Application Scanned	
1	10-18-2000	Initial Exam Team nn	

3/27/2003


3/27/2003

HOME | INDEX | SEARCH | SYSTEM ALERTS | BUSINESS CENTER | NEWS&NOTICES | CONTACT US | PRIVACY STATEMENT

Exhibite

# RETURN RECEIPT CARD

(MPEP § 503)



Application of:

Ruben et al.

Docket No.: PZ006P1C1

Application Serial No.: 09/690,454-Conf. #1914

Art Unit: 1653

Filed: October 18, 2000

Examiner: K. Carlson

Title: Secreted Protein HEMCM42

The following documents were filed by Human Genome Sciences, Inc. via hand delivery on January 15, 2003:

- 1. Return Receipt Card;
- 2. Fee Transmittal charging \$1,327.00 to deposit account (in duplicate);
- 3. Issue Fee Transmittal;
- 4. Part B-Fee(s) Transmittal w/appropriate fee (in duplicate);
- 5. Letter Making Patent Office Error of Record;
- 6. Copy of Marked-Up Official Filing Receipt; and
- 7. Copy of previously submitted Preliminary Amendment and PTO date-stamped postcard evidencing receipt of same.

# RETURN RECEIPT CARD

(MPEP § 503)

OIPE:	Please Date Stamp In The Box Below And Return To Addressee
į	

Application of:

Ruben et al.

Application Serial No.: 09/690,454-Conf. #1914

Art Unit: 1653

Filed: October 18, 2000

Examiner: K. Carlson

Docket No.: PZ006P1C1

Title: Secreted Protein HEMCM42

The following documents were filed by Human Genome Sciences, Inc. via hand delivery on January 15, 2003:

- 1. Return Receipt Card;
- 2. Fee Transmittal charging \$1,327.00 to deposit account (in duplicate);
- 3. Issue Fee Transmittal;
- 4. Part B-Fee(s) Transmittal w/appropriate fee (in duplicate);
- 5. Letter Making Patent Office Error of Record;
- 6. Copy of Marked-Up Official Filing Receipt; and
- 7. Copy of previously submitted Preliminary Amendment and PTO date-stamped postcard evidencing receipt of same.

PTO/S8/17 (10-02)
Approved for use through 10/31/2002. OMB 0651-0032
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FFF TO A MONITTAL		Complete if Known				
FEE TRANSMITTAL		Appli	Application Number 09/690,454-Conf. #			
for FY 2003		Filing Date			October 18, 2000	
Patent fees are subject to annual revision.		First Named Inventor			entor Steven M. Ruben	
Y down rees are subject to dimension.		Exam	iner N	ame	K. Carlson	
Applicant claims small entity status. See 37 CFR 1.27		Group	o Art U	nit	1653	
TOTAL AMOUNT OF PAYMENT (\$) 1,327.00		Attorr	ey Do	cket N	lo. PZ006P1C1	
METHOD OF PAYMENT (check all that apply)	ī			FEE	E CALCULATION (continued)	
Check Credit Money Other None	3 4	DDITI	ONAL			
Card Urder	J. 7		01172		•	
X Deposit Account		e Entity	Small	Entity		
Deposit Account 08-3425	Fee	Fee	Fee	Fee	<del></del> -	
Number	Code	(\$)	Code	(\$)	Fee Paid	
Deposit   Account   Human Genome Sciences, Inc.	1051	130	2051	65	Surcharge – late filing fee or oath	
Name The Commissioner is hereby authorized to: (check all that apply)	1052	50	2052	25	Surcharge – late provisional filing fee or cover sheet.	
X Charge fee(s) indicated below X Credit any overpayments	1053	130	1053	130	Non-English specification	
Charge any additional fee(s) during the pendency of this						
application	1812	2,520	1812		For filing a request for ex parte reexamination  Requesting publication of SIR prior to	
Charge fee(s) indicated below, except for the filing fee	1804	920*	1804	920*	Examiner action	
to the above-identified deposit account.	1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
FEE CALCULATION	1251	110	2251	55	Extension for reply within first month	
1. BASIC FILING FEE	1252	400	2252	200	Extension for reply within second month	
Large Entity Small Entity	1253	920	2253	460	Extension for reply within third month	
Fee Fee Fee Fee <u>Fee Description</u> Fee Paid	1254	1,440	2254	720	Extension for reply within fourth month	
1001 740 2001 370 Utility filing fee	1255	1,960	2255	980	Extension for reply within fifth month	
1002 330 2002 165 Design filing fee	1401	320	2401	160	Notice of Appeal	
1003 510 2003 255 Plant filing fee 1004 740 2004 370 Reissue filing fee	1402	320 280	2402 2403	160 140	Filing a brief in support of an appeal  Request for oral hearing	
1004 740 2004 370 Reissue filing fee 1005 160 2005 80 Provisional filing fee	1451	1,510	1451	1.510	· · · · · · · · · · · · · · · · · · ·	
	1452	110	2452	55	Petition to revive – unavoidable	
SUBTOTAL (1) (\$) 0.00	1453	1,280	2453	640	Petition to revive - unintentional	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1501	1,280	2501	640	Utility issue fee (or reissue) 1,300.00	
Extra Fee from Claims below Fee Paid	1502	460	2502	230	Design issue fee	
Total Claims -** = \ x = 0.00	1503	620	2503	310	Plant issue fee	
Independent = x = 0.00	1460	130	1460	130	Petitions to the Commissioner	
Multiple Dependent	1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
Large Entity Small Entity	1806	180	1806	180	Submission of Information Disclosure Stmt	
Fee Fee Fee Fee Fee Description	8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1202 18 2202 9 Claims in excess of 20	1809	740	2809	370	Filing a submission after final rejection (37 CFR 1.129(a))	
1201 84 2201 42 Independent claims in excess of 3	1810	740	2810	370	For each additional invention to be	
1203 280 2203 140 Multiple dependent claim, if not paid 1204 84 2204 42 ** Reissue independent claims	1801	740	2801	370	examined (3/CFR 1.129(b))	
over original patent	1802	900	1802	900	Request for expedited examination	
1205 18 2205 9 ** Reissue claims in excess of 20 and over original patent		1			of a design application	
		ee (spec		8001	Printed copy of patent w/o color (9@\$3.00) 27.00	
SUBTOTAL (2) (\$) 0.00  **or number previously paid, if greater; For Reissues, see above	*Redu	ced by 8	Basic Fil	ing Fee	e Paid SUBTOTAL (3) (\$) 1,327.00	
SUBMITTED BY					Complete (if applicable)	
		ation No	16	,903	Telephone (301) 315-2723	
	(Attorne	y/Agent)	140	,303	<del></del>	
Signature / //////////////////////////////////	1				Date January 15, 2003	

In re Patent Application of:

Docket No.: PZ006P1C1

Ruben et al.

Application No.: 09/690,454

Allowed: October 16, 2002

Filed: October 18, 2000

Group Art Unit: 1653

For: Secreted Protein HEMCM42

Examiner: K. Carlson

### ISSUE FEE TRANSMITTAL

**Box Issue Fee** 

Commissioner for Patents Washington, DC 20231

Dear Sir:

In response to the Notice of Allowance and Fee(s) Due mailed October 16, 2002, Applicants submit herewith:

- 1. a Fee Transmittal Sheet, with appropriate fee(s); and
- 2. Part B Fee(s) Transmittal (Form PTOL-85), with fee(s).

The U.S. Patent and Trademark Office is hereby authorized to charge any deficiency in the fees filed, or credit any overpayment, to our Deposit Account No. 08-3425.

Dated: January 15, 2003

Respectfully submitted,

Janet M. Martineau
Registration No.: 46,903

HUMAN GENOME SCIENCES, INC.

9410 Key West Avenue Rockville, Maryland 20850

(301) 315-2723

### PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Box ISSUE FEE

Commissioner for Patents

Washington, D.C. 20231

(703)746-4000

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks I through 4 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block I, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Legibly mark-up with any corrections or use Block 1) Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission. 10/16/2002 22195 7590 HUMAN GENOME SCIENCES INC Certificate of Mailing or Transmission
I hereby certify that this Fee(s) Transmittal is being deposited with the
United States Postal Service with sufficient postage for first class mail in a
envelope addressed to the Box Issue Fee address above, or being facsimile
transmitted to the USPTO, on the date indicated below. 9410 KEY WEST AVENUE ROCKVILLE, MD 20850 (Depositor's name) (Signature (Date) FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. APPLICATION NO. FILING DATE PZ006P1C1 1914 09/690.454 10/18/2000 Steven M. Ruben TITLE OF INVENTION: SECRETED PROTEIN HEMCM42 TOTAL FEE(S) DUE DATE DUE ISSUE FEE PUBLICATION FEE APPLN. TYPE SMALL ENTITY 01/16/2003 nonprovisional NO \$1280 \$1300 EXAMINER ART UNIT CLASS-SUBCLASS CARLSON, KAREN C 1653 536-023100 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). 2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys HUMAN GENOME SCIENCES, or agents OR, alternatively, (2) the name of a ☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. INC. single firm (having as a member a registered attorney or agent) and the names of up to 2 ☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. registered patent attorneys or agents. If no name is listed, no name will be printed. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) ROCKVILLE, MD HUMAN GENOME SCIENCES, INC. ☐ individual 🛮 corporation or other private group entity ☐ government Please check the appropriate assignee category or categories (will not be printed on the patent) 4a. The following fee(s) are enclosed: 4b. Payment of Fee(s): A check in the amount of the fee(s) is enclosed. **X**Issue Fee Payment by credit card. Form PTO-2038 is attached. D Publication Fee The Commissioner is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 08-3425 (enclose an extra copy of this form). XAdvance Order - # of Copies \_ Commissioner for Patents is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. (Authorized 8) ggazute) (Date) Janet M. Janet M. Martineau, Reg. No. 46,903

NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office. This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

In re Patent Application of:

Docket No.: PZ006P1C1

Ruben et al.

Application No.: 09/690,454 Allowed: October 16, 2002

Filed: October 18, 2000 Group Art Unit: 1653

For: Secreted Protein HEMCM42 Examiner: K. Carlson

### LETTER MAKING PATENT OFFICE ERROR OF RECORD

Commissioner for Patents Washington, DC 20231

Dear Sir:

Applicants hereby submit that the Continuing Data stated on the official filing receipt, mailed January 15, 2001 contains an error committed by the Patent Office. Specifically, the priority information should read as follows:

This application is a CN of 09/189,144 11/10/1998 ABN which is a CIP of PCT/US98/10868 05/28/1998 which claims benefit of 60/044,039 05/30/1997 and claims benefit of 60/048,190 05/30/1997 and claims benefit of 60/048,190 05/30/1997 and claims benefit of 60/050,935 05/30/1997 and claims benefit of 60/048,101 05/30/1997 and claims benefit of 60/048,356 05/30/1997 and claims benefit of 60/056,250 08/29/1997 and claims benefit of 60/056,296 08/29/1997 and claims benefit of 60/056,293 08/29/1997 and claims benefit of 60/056,293 08/29/1997 and a CIP of PCT/US98/10868 05/28/1998

Applicants hereby submit that the error was committed by the Patent Office as evidenced by Applicants' Preliminary Amendment filed on October 18, 2000 (a copy of which is submitted herewith along with a copy of the date-stamped postcard). Applicants respectfully request that this Letter by made of record in the above-identified file, pursuant to MPEP §1480.

No fees are believed due with the submission of this Letter. However, should the Patent Office deem otherwise, the Patent Office is hereby authorized to charge any deficiency in the fees filed, or credit any overpayment, to our Deposit Account No. 08-3425.

Dated: January 15, 2003

Respectfully submitted,

Janet M. Martineau

Registration No.: 46,903

HUMAN GENOME SCIENCES, INC.

9410 Key West Avenue

Rockville, Maryland 20850

(301) 315-2723



### United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20 23

1	APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
,	09/690,454	10/18/2000	1631	862	PZ006P1C1	•	24	4

Kenley K Hoover Esq Human Genome Sciences Inc 9410 Key West Avenue Rockville, MD 20850 JAN 18 2001 \*OC000000005678959\*

KKH SA ZS

Date Mailed: 01/15/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you-received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

### Applicant(s)

Steven M. Ruben, Olney, MD;
Craig A. Rosen, Laytonville, MD;
Kenneth C. Carter, North Potomac, MD;
Patrick J. Dillon, Carlsbad, CA;
Gregory A. Endress, Potomac, MD;
Guo-Liang Yu, Berkeley, CA;
Jian Ni, Rockville, MD;
Ping Feng, Gaithersburg, MD;

### Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CON OF 09/189,144 11/10/1998 ABN
WHICH CLAIMS BENEFIT OF 60/044,039 05/30/1997
AND CLAIMS BENEFIT OF 60/048,190 05/30/1997
AND CLAIMS BENEFIT OF 60/050,935 05/30/1997
AND CLAIMS BENEFIT OF 60/048,101 05/30/1997
AND CLAIMS BENEFIT OF 60/048,356 05/30/1997
AND CLAIMS BENEFIT OF 60/056,250 08/29/1997
AND CLAIMS BENEFIT OF 60/056,293 08/29/1997

### Foreign Applications

If Required, Foreign Filing License Granted 01/07/2001

# HUMAN GENOME SCIENCES, INC.

Please date stamp and return to addressee on reverse side

Applicants: Ruben et al.

Docket No. PZ006P1C1

Application No.: Unassigned

Filed: herewith

Title: 32 Human Secreted Proteins

### Documents Filed Via Hand Delivery on October 18, 2000

- 1. Postcards (2);
- 2. Utility Patent Application Transmittal (CON) w/ 147 pgs. spec.
- 3. Fee Transmittal Sheet (in dupl.);
- 4. Preliminary Amendment;
- 5. Copy of Declaration of parent application (15 pgs.);
- 6. Request Under 37 CFR 1.821(e);
- 7. Copy of Petition for Extension of Time filed concurrently w/ parent application;
- 8. 102 pgs. of Sequence Listing in paper form.

OCT 1 8 2000

Application of: Ruben et al.

Application Number: to be assigned Group Art Unit: to be assigned

Filed: herewith Examiner: to be assigned

Title: 32 Human Secreted Proteins Attny. Docket No. PZ006P1C1

### PRELIMINARY AMENDMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Prior to the prosecution of the above-captioned application, please enter the following amendments. Applicants submit concurrently herewith a copy of the Petition for Extension of Time under 37 C.F.R. § 1.136 ("Petition") filed in connection with parent application no. 09/189,144, which extends the time from June 18, 2000 to and including October 18, 2000. This Petition evidences copendency between parent application Serial No. 09/189,144 and the present application.

### Amendments

### In the Specification

Page 1, first paragraph, change "This application is a continuation-in-part of, and claims benefit under 35 U.S.C. § 120 of copending United States patent application Serial No: PCT/US98/10868, filed May 28, 1998, which is hereby incorporated by reference, which claims benefit under 35 U.S.C. § 119(e) based on U.S. Provisional Applications:" to -- This application is a Continuation of U.S. Application No, 09/189,144 filed November 10, 1998, which is hereby incorporated by reference, which is a continuation-in-part of, and claims benefit under 35 U.S.C. § 120 of copending United States patent application Serial No. PCT/US98/10868, filed May 28, 1998, which is hereby incorporated by reference, and which claims benefit under 35 U.S.C. § 119(e) based on the following U.S. Provisional Applications, all of which are hereby incorporated by reference: --

In the Claims

Please amend the claims as follows:

Claim 17, delete "or the polynucleotide of claim 1".

Please add the following claim:

-- 24. A method for preventing, treating, or ameliorating a medical condition,

comprising administering to a mammalian subject a therapeutically effective amount

of the polynucleotide of claim 1. --

REMARKS

The specification has been amended to add priority information. The claims

have been amended to more particularly point out and distinctly claim the subject

matter applicants regard as the invention. Support for new claim 24 can be found

throughout the application as filed.

No new matter has been introduced.

Applicants believe that no fee is required for this submission. However,

should a fee be due, please charge such fee to Deposit Account No. 08-3425

Respectfully submitted

Date: October 18 zecc

Kenley K. Hoover (Reg. No. 40,302)

Attorney for Applicants

Human Genome Sciences, Inc.

9410 Key West Avenue Rockville, MD 20850

(301) 610-5771 (telephone)

KKH/SA/ur